Skye Bioscience Signs Arrangement Agreement With Emerald Health Therapeutics, Here Are The Details
Skye Bioscience Signs Arrangement Agreement With Emerald Health Therapeutics, Here Are The Details
Skye Bioscience与Emerald Health Treateutics签署安排协议,详情如下
Skye Bioscience, Inc. (OTCQB:SKYE) and Emerald Health Therapeutics, Inc. (OTCQB:EMHTF) (CSE:EMH) have entered into a definitive agreement with respect to a transaction to be completed by way of a plan of arrangement whereby Skye would acquire all of the issued and outstanding shares of Emerald in a share-for-share-transaction.
斯凯生物科学公司。(OTCQB:Skye)和Emerald Health Treateutics,Inc.。(场外交易代码:EMHTF)(CSE:EMH)已经达成了一项最终协议关于以安排计划的方式完成的交易据此,Skye将收购Emerald的所有已发行和流通股在以股换股的交易中。
Skye is a San Diego-based pharmaceutical company developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet needs. Emerald possesses cash and non-cash assets that Skye would acquire through the arrangement. The proposed arrangement is subject to approval by each...
斯凯是一家总部位于圣地亚哥的制药公司开发专有的合成大麻素衍生物,用于治疗青光眼和其他有重大未...
登录免费看全文
登录/注册